endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

R&D channel feed

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

5 months ago

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

5 months ago

Q32 Bio’s stock crash­es af­ter atopic der­mati­tis fail, alope­cia tri­al sna­fu

5 months ago

The End­points 100: The biotech in­dus­try braces for Trump 2.0

5 months ago
Deals
Bioregnum

Bay­er ex­its Eu­rope pact with Moberg for nail fun­gus drug af­ter Phase 3 fail

5 months ago
Deals

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

5 months ago

NewAms­ter­dam hits pri­ma­ry end­point in lat­est Phase 3 tri­al of CETP in­hibitor

5 months ago
Pharma

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

5 months ago
FDA+

Cardiff un­veils pos­i­tive Phase 2 da­ta for col­orec­tal can­cer drug, $40M of­fer­ing

5 months ago

Halia Ther­a­peu­tics takes NL­RP3 in­hibitor in­to fi­nal stage of Phase 2 tri­al

5 months ago

Ear­ly da­ta sug­gest Arv­inas, Pfiz­er could com­bine their breast can­cer drug with Lil­ly’s Verzenio

5 months ago

BioN­Tech re­ports ear­ly sur­vival da­ta for VEGF bis­pe­cif­ic, weeks af­ter buy­ing Chi­nese part­ner

5 months ago

Ole­ma On­col­o­gy makes case for its oral SERD with fresh da­ta cut from ear­ly breast can­cer tri­al

5 months ago

BTK in­hibitors from As­traZeneca, Eli Lil­ly and BeiGene take cen­ter stage in CLL

5 months ago
Pharma

Ar­cel­lx and Gilead seek to un­seat Leg­end and J&J with mul­ti­ple myelo­ma cell ther­a­py

5 months ago
Pharma
Cell/Gene Tx

Ku­ra On­col­o­gy de­tails 'ag­gres­sive' ap­proach in first-line AML

5 months ago

Ret­ro­spec­tive analy­sis shows po­ten­tial for GLP-1s to treat blood clots

5 months ago
Pharma

GSK re­ports Blenrep over­all sur­vival da­ta in mul­ti­ple myelo­ma as it plots mar­ket reen­try

5 months ago
Pharma

ICER finds Ver­tex's non-opi­oid pain treat­ment could bring cost sav­ings at a low­er price

5 months ago
Pharma

Ab­b­Vie, Gen­mab tout Ep­kin­ly com­bos in ear­li­er lines of non-Hodgkin lym­phoma

5 months ago
Pharma

Ab­b­Vie de­clares third Phase 3 Parkin­son’s win from Cerev­el takeover

5 months ago
Pharma

Mer­ck­'s Keytru­da com­bo miss­es over­all sur­vival in Phase 3 tri­al in ovar­i­an can­cer

5 months ago

Beam shares re­sults from sev­en pa­tients who re­ceived gene-edit­ed sick­le cell ther­a­py

5 months ago
Cell/Gene Tx

As­traZeneca re­veals first clin­i­cal da­ta for bis­pe­cif­ic T cell en­gager from TeneoT­wo buy­out

5 months ago
First page Previous page 15161718192021 Next page Last page
A service from the Financial Times